Document:

Exhibit 4.3

 

NOTATION OF GUARANTEE

 

For value received, the Guarantor (which term includes any successor Person under the Indenture hereinafter referred to) has unconditionally guaranteed to the extent set forth in, and subject to the provisions of, an indenture dated as of September 16, 2011 (the “Base Indenture”), as amended by the First Supplemental Indenture, dated as of June 26, 2012 (the “First Supplemental Indenture” and, together with the Base Indenture and as the Base Indenture and the First Supplemental Indenture may be further amended and supplemented from time to time, the “Indenture”) among CubeSmart, L.P. (the “Issuer”), the Guarantor named therein and U.S. Bank National Association, as trustee (the “Trustee”), providing for the issuance of 4.80% Senior Notes due 2022, the due and punctual payment of the principal of and interest on the Notes to which this notation is affixed and all other amounts due and payable under the Indenture and the Notes to which this notation is affixed by the Issuer.

 

The obligations of such Guarantor to the Holders of Notes to which this notation is affixed and to the Trustee pursuant to the Guarantee and the Indenture are expressly set forth in Article Fourteen of the Indenture and reference is hereby made to the Indenture for the precise terms of the Guarantee.

 

	
 
    	
CUBESMART
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Timothy M. Martin
    
	
 
    	
Name:
    	
Timothy M. Martin
    
	
 
    	
Title:
    	
Senior Vice President and
    
	
 
    	
 
    	
Chief Financial OfficerExhibit 10.1

 

 

Assigned Task Agreement 

Between Konica Minolta Technology
Center, Inc. (KMTC) and Guided Therapeutics, Inc. (GT)

Agreement for the Development
of Spectroscopy for Barrett's Esophagus 

"Project Sangam"

CONFIDENTIAL

This Agreement is made on this
1st day of May, 2012 (the "Effective Date") between Guided Therapeutics, Inc., having a place of business 5835 Peachtree
Comers East Suite D, Norcross, Georgia, 30992 ("GT") and Konica Minolta Technology Center, Inc., having an address of
I Sakura-machi, Hino-shi, Tokyo 191-8511, Japan ("KMTC"), each individually referred to herein as a "party"
and collectively referred to as the "Parties".

WHEREAS, GT and Konica Minolta
Opto, Inc., having an address of 5835 Peachtree Corners East, Suite D, Norcross, GA 30092 ("GT") and Konica Minolta Opto,
Inc, having a place of business at 2970 Ishikawa-machi, Hachioji-shi, Tokyo 192-8505, Japan ("KMOT") have executed an
option-to-license and no-shop agreement dated March 28, 2011 ("2011 Option Agreement").

WHEREAS, GT and KMOT have also
executed an Assigned Task Agreement for the Development of Spectroscopy for Barrett's Esophagus ("Project Sangam ") dated
May 1, 2011.

WHEREAS, KMTC has succeeded to
the 2011 Option Agreement and the above Assigned Task Agreement from KMOT.

WHEREAS, both GT and KMTC wish
to continue the Assigned Task Agreement for the Development of Spectroscopy for Barrett's Esophagus (“Project Sangam”)
under the terms and conditions described herein.

NOW THEREFORE, and in consideration
of the mutual promises and covenants herein contained and intending to be legally bound, GT and KMTC agree as follows:

		1.	All terms and conditions of the 2011 Option Agreement and any extensions
remain in full effect and force. 

		2.	This Agreement is adjunctive to the 2011 Option Agreement under Sections
4 and 5 of that Agreement and should in no way be construed as further modifying or superseding the 2011 Option Agreement and continuations
or extensions thereof. 

		3.	KMTC agrees to utilize the technical, regulatory and clinical expertise
of GT in order to develop GT's spectroscopic technology for the purposes of detecting cancer and pre-cancer of the human esophagus.
A preliminary schedule and budget for this work is attached to this Agreement as Exhibits A and B. GT shall use its best efforts
to collaborate with KMTC for accomplishing the tasks described in Exhibits A and B. 

		4.	Tasks performed by GT and payment in return from KMTC to GT shall
be under the following terms and conditions: 

		a)	Schedule for Performing Tasks – The project shall commence
on May 1, 2012 and is anticipated to be completed by April 30, 2013, as summarized in Exhibit A. 

The primary tasks of GT
shall be as follows:

		-	Produce additional clinical prototypes,
or modifications thereof as needed for algorithm training study.

		-	Negotiate with IRB and Clinical Investigators
for clinical studies.

		-	Conduct and manage the algorithm training
study.

		-	Write up results and feedback from algorithm
training study.

		-	Negotiate with FDA as needed.

		-	Conduct Single Batch Release Validation
for Fiber Optic Probes for algorithm training study, if needed. Is outside of the budget and would be billed separately, if needed.

		-	Redesign and production of clinical prototypes
if necessary. In this case, the budget may be reconsidered. 

		b)	Primary Tasks – KMTC 

		-	Produce Fiber Optic Probes for the study.

		-	Attend the algorithm training study.

		-	Assist with results and feedback from algorithm
training study.

		-	Redesign and production of Fiber Optic Probes
if necessary. 

		c)	Payment Schedule, as summarized in Exhibit B, of the project budget,

		i)	First payment $660,000 due June 30, 2012 or earlier

		ii)	Second payment $310,000 due July 31, 2012 or earlier

		iii)	Third payment $320,000 due October 31, 2012 or earlier

		iv)	Fourth payment $310,000 due January 31, 2013 or earlier 

		e)	Review of the achievement of GT's Tasks 

		v)	First Review: October 2012

		vi)	Second Review: January 2013 

     

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed by their duly authorized officers as of the day of June 19, 2012.

	 	 	 
	 GT KMTC	 	KMTC
	5835 Peachtree Corners East Suite D	 	1 Sakura-machi, Hino-shi
	Norcross, Georgia 30092	 	Tokyo 191-8511, Japan
	 	 	 
	 	 	 
	By: /s/ Mark Faupel	 	By: /s/ Tamaki Nara
	Mark Faupel, PhD	 	Tamaki Nara
	President and CEO	 	General Manager
	 	 	Business Development Center
	 	 	LC Business DepartmentExhibit 10.2

 

Agreement for Collaboration in
the Development of Spectroscopic Technology

This Agreement for Collaboration
in the Development of Spectroscopic Technology, as extended pursuant to Section II of the March 28, 2011 Agreement for Collaboration
in the Development of Spectroscopic Technology between Guided Therapeutics, Inc., having a place of business at 5835 Peachtree
Comers East, Suite 0, Norcross, GA 30092 ("GT") and Konia Minolta Opto, Inc., having a place of business at 2970 Ishikawa-machi,
Hachioji-shi, Tokyo 1928505, Japan (the "Agreement"), is made on this)" day of May, 2012 (the "Effective Date")
between GT and Konica Minolta Technology Center, Inc., having an address of 1 Sakuramachi, Hino·shi, Tokyo 191-8511 , Japan,
("KMTC"), which has succeeded to the Agreement from Konica Minolta Opto, Inc., each of GT and KMTC individually referred
to herein as a "party" and collectively referred to as the "Parties".

WHEREAS, GT, among other things,
has proprietary business, technical expertise and knowhow relating to tissue spectroscopy including but not limited to cancer detection.

WHEREAS, KMTC has proprietary
technical, business and marketing expertise relating to medical devices and optical systems; and

WHEREAS, GT and KMTC desire and
seek to enter into collaboration to research and develop the aforementioned technologies in specific medical markets wherein KMTC
would gain access to GT's technology.

NOW THEREFORE, and in consideration
of the mutual promises and covenants herein contained and intending to be legally bound, GT and KMTC agree as follows:

		1.	DEFINITIONS 

	"Confidential Information"
means trade secrets, materials and other proprietary information of a secret and confidential nature, which information and materials
are proprietary to a party, or which a party has received from a third party under an obligation of confidentiality. Confidential
Information may include, but is not limited to, financial information, business and/or development plans, records, data, formulae,
processes, know-how, developments, designs, inventions (whether patentable or not), models, clinical protocols and study designs,
techniques, improvements and/or discoveries.
	"GT Spectroscopic Intellectual
Property" shall mean all of GT's, and its affiliate company's, rights, title and interests to all intellectual property including,
without limitation, any patents, patent applications, or ideas inventions, discoveries, improvements, design rights, trade secrets,
know-how, works of authorship, and equivalents thereof, whether or not protectable by patent, trade secret or copyright which exist
as of the Effective Date or hereafter acquired by GT in the field of tissue spectroscopy.
	For GT Spectroscopic Intellectual Property
"the Spectroscopy Fields" shall mean the Spectroscopy measurement of tissue, both in vivo and in vitro, in the upper
GI/esophageal disease, including specifically the condition known as Barrett's esophagus.

		2.	COOPERATION WITH AFFILIATED GROUPS 

	During the term of this Agreement,
KMTC may cooperate with its affiliated companies and with other consulting companies under this agreement ("KM Group").
	During the Term of this Agreement,
GT may cooperate with InterScan, Inc. under this agreement. ("InterScan Group")

		3.	TECHNOLOGY ASSESSMENT AND OPTION TO LICENSE 

During the term of this
Agreement, GT hereby grants to KMTC and its affiliates an exclusive option to negotiate an exclusive or nonexclusive license and/or
marketing agreement in the Spectroscopy Fields under the GT Spectroscopic Intellectual Property during the period set forth below
and any extension thereto in accordance with this Agreement, to allow opportunity KMTC and its affiliates to conduct a development
activities for the technologies in the Spectroscopy Fields as defined in Section 4. below.

		4.	LIMITATION OF AGREEMENT AND NO SHOP. 

This Agreement is limited
to providing KMTC or its affiliate's exclusive access to GT's technology in the Spectroscopy Fields as defined in Section 1c. above
for the purposes of developing products in the Spectroscopy Fields.

With regard to the development
of products within the Spectroscopy Fields, GT agrees not to solicit, initiate, encourage or engage in discussions or negotiations
with, or provide any information to, or take any other action to otherwise facilitate the efforts of, any third party with respect
to (i) conducting a transaction similar to a future proposed transaction with any party other than KMTC and its affiliates, or
(ii) entering into any agreement that would otherwise be inconsistent with the terms of this Agreement, or that would prohibit
the performance of GTs obligations contemplated herein or that could be expected to diminish the likelihood of or render impracticable
the consummation of a proposed future transaction.

Notwithstanding the foregoing,
this Agreement does not provide any rights to KMTC or its affiliates to market, sell and/or license products and/or intellectual
property in the Spectroscopy Fields, such rights to be negotiated during the term of this Agreement and then specified in a future
agreement.

		5.	RESPONSIBILITIES DURING TERM OF AGREEMENT 

	Both parties agree that this Development
Agreement also has as its purpose to allow progress to be made in the Spectroscopy Fields prior to the execution of a more comprehensive
technology licensing and/or marketing agreement that is mutually agreeable to both parties.
	In recognition of the exclusive development
and technology rights granted to KMTC and its affiliates as described herein, KMTC will pay to GT according to the following schedule:
$400,000 due on or before June 30, 2012.

These rights include:

		·	the exclusive rights for the term of this
Agreement described in Section 4 above. Access to GT intellectual property and know-how in the Spectroscopy Fields as defined in
Section 1c. above. 

		·	the disclosure and collaborative development
of GT's technologies in the Spectroscopy Fields as defined in Section 1c. above. 

		·	Option to negotiate a technology licensing
and/or marketing agreement in the Field's of Use during the term of this Agreement. 

	In addition to the rights granted to
KMTC described in Section 5b above, GT will furnish, in advance, written estimates to KMTC of costs for accomplishing tasks assigned
to GT and KMTC will reimburse GT for expenses in accomplishing those tasks mutually agreed to.

		6.	PROPOSED TASKS AND GOALS 

		•	The proposed tasks for the work to be performed under this Agreement
include but are not limited to the following: 

GT tasks would include:

	Working with KMTC to develop specifications
in the Spectroscopy Fields, GT would take the lead on the requirements documents and timeline with assistance from KMTC.
	Working with KMTC to adapt its cancer
detection platform for use in the Spectroscopy Fields.
	Responsibility for the following aspects
of developing new devices in the Spectroscopy Fields as described below:

		·	Determine Spectroscopy wavelengths for a
given organ in the Spectroscopy Fields 

		·	Determine the optical platform for said
devices 

		·	Design and build the base unit for said
devices including, but not limited to the power supply, lamp or other illumination source, spectrometer, optical fibers and filters.

		·	Design and write the software for calculating
and producing a result from the Spectroscopy data 

		·	Clinical and regulatory implementation at
US hospitals and/or clinics under IRB approved protocols and US FDA good clinical practice guidelines. 

	Supplying KMTC with any hardware and
software under mutually agreed to purchase orders.
	Using reasonable efforts to maintain
the patent portfolio necessary for effective commercialization of products in the Spectroscopy Fields in both the United States
and Japan.

 

KMTC tasks would include:

	Assisting GT in the marketing
activities related to the commercialization of GT's technologies in the Spectroscopy Fields. This activity would include contributing
marketing information needed to define the operating characteristics of the technologies under development and to assist in writing
the Product Requirements documentation.
	KMTC shall have responsibility for
the following aspects of new devices in the Spectroscopy Fields as described below:

		·	Design and build the lens trains 

		·	Design and build the probes, such as the
endoscopic means of accessing tissue for the means of Spectroscopy measurements 

		7.	OWNERSHIP OF INVENTIONS 

All technology invented
solely by GT employees, agents or contractors shall be the property of GT and all such inventions in the Spectroscopy Fields shall
be promptly disclosed in writing to KMTC, and shall be subject to the license. All technology invented by GT, its employees, agents
or contractors outside the Spectroscopy Fields or acquired or licensed by GT outside the Spectroscopy Fields, are the sole property
of GT, and GT shall have no obligation hereunder to grant a license under such technology to KMTC.

All technology invented
solely by KMTC employees, agents or contractors shall be the property of KMTC and all such technology shall be promptly disclosed
in writing to GT.

All technology invented
by at least one employee, agent or contractor of KMTC and at least one employee, agent or contractor of GT shall be the joint property
of KMTC and GT.

		8.	PUBLICITY 

The terms and conditions
of this Agreement shall be confidential and neither party shall disclose the terms and conditions of this Agreement to any other
party outside of KM Group or GT Group. Neither party shall make any press release or other public announcements with respect to
this Agreement without the consent of the other party unless required by law.

		9.	DISCLAIMER 

GT AND KMTC DISCLAIM ANY
AND ALL WARRANTIES BOTH EXPRESSED AND IMPLIED WITH RESPECT TO THE PRODUCTS PROVIDED, OR THE SERVICES TO BE PERFORMED HEREUNDER
AND ANY DELIVERABLES RESULTING THEREFROM, INCLUDING THEIR CONDITION, CONFORMITY TO ANY REPRESENTATION OR DESCRIPTION, THE EXISTENCE
OF ANY LATENT OR PATENT DEFECTS THEREIN, AND THEIR MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE. All information
is provided on as AS-IS basis.

		10.	LIMITATIONOFLIABILITY 

Neither party will be
liable for any business expense, machine down time, loss of profits, any incidental, special, exemplary or consequential damages,
or any claims or demands brought against by the other party or the other party's customers, even if such party has been advised
of the possibility of such claims or demands. The foregoing limitations of liability, damages and claims are intended to survive
termination of this Agreement.

		11.	TERM OF AGREEMENT, TERMINATION AND OPTION TO EXTEND 

This Agreement shall be
effective on April 29, 2012 upon execution and shall continue until April 28, 2013. If both KMTC and GT agree in writing, this
Agreement can be extended for an additional one year.

		12.	CONFIDENTIALITY 

	Except as set forth below, any information
disclosed by either party to the other during the term of this Agreement in connection with the activities contemplated hereby,
any samples provided, the facilities or records of either party shall be considered proprietary and "Confidential Information"
of the disclosing party, provided that the Confidential Information shall be disclosed by any of the following methods:

		i)	Disclosure in written form which is clearly marked "Confidential"
or otherwise marked as such (including information disclosed electronically such as via facsimile or e-mail); or 

		ii)	Disclosure through tangible object with a notice which is clearly
marked "Confidential" or otherwise marked as such; or 

		iii)	Oral disclosure; provided, however, the disclosing party shall identify
such disclosure as being "Confidential" at the time of disclosure and send to the receiving party, within thirty (30)
days after such disclosure, documents clearly marked "Confidential" or otherwise marked as such and describing such information
to be deemed as Confidential Information. 

	Notwithstanding the foregoing, "Confidential
Information" shall not include information which:

		i)	Was publicly available at the time of the disclosure to the receiving
party; 

		ii)	Subsequently becomes publicly available other than as a result of
a disclosure in violation of this Agreement; 

		iii)	Can be demonstrated by written record to already be in the possession
of the receiving party at the time of this Agreement; 

		iv)	Is rightfully acquired by the receiving party, subsequent to disclosure
by the other party, from a third party who, to the receiving party's knowledge, is not in breach of a confidentiality obligation
with regard to such information; 

		v)	Is independently developed by the receiving party solely through
the efforts of individuals who did not have access to the Confidential Information; or 

		vi)	Is disclosed with the prior written consent of the party from whom
the information was received. 

	Unless otherwise provided, each party
agrees not to disclose any other Confidential Information and not to use such Confidential Information for its own benefit except
as specifically provided in this Agreement and except that either party may disclose such information to those of its employees
and agents in the GT Group or KM Group who have a need to know the Confidential Information. In addition, GT Group and KM Group
must maintain appropriate confidentiality agreements for subcontractors if said subcontractors receive confidential information
as defined in this Agreement. The covenants made in this Section 12 shall commence on the date hereof and shall expire on the fifth
(5th) anniversary of the termination or expiration of this Agreement. The receiving party shall have no obligation with respect
to the Confidential Information after such period.
	Each party hereby acknowledges and
agrees that the prohibitions against disclosure of Confidential Information recited herein are in addition to, and not in lieu
of, any rights or remedies that each party may have available pursuant to the laws of any jurisdiction or at common law to prevent
the disclosure of trade secrets or proprietary information, and that the enforcement by a party of its rights and remedies pursuant
to this Agreement shall not be construed as a waiver of any other rights or available remedies in law or equity absent this Agreement
except as required by law.
	If either party believes it is required
by law or by a subpoena or by a court order to disclose any of the other party's Confidential Information, it shall promptly notify
the other party prior to any disclosure and shall make all reasonable efforts to allow the other party an opportunity to seek a
protective order or other judicial relief.
	Each party hereby acknowledges that:
(i) the provisions of this Agreement are fundamental to the protection of the other party's legitimate business interests; (ii)
such provisions are reasonable and appropriate in all respects; and (iii) in the event it violates any such provisions, the other
party would suffer irreparable harm and its remedies at law would be inadequate. Accordingly, in the event a party or its representatives
violate any such provisions, the other party shall be entitled to a temporary restraining order, temporary and permanent injunctions,
specific performance, and other equitable relief without any showing of irreparable harm or damage or the posting of any bond,
in addition to any other rights or remedies which may then be available to the other party.

		13.	MISCELLANEOUS 

	All notices and other communication
required or permitted to be given under this Agreement will be effective upon deposit in the mail, postage prepaid and addressed
to the parties at their respective addresses set forth below unless by such notice a different person or address shall have been
designated.

	 	If to GT:	Mark Faupel	 
	 	 	Guided Therapeutics, Inc.	 
	 	 	5835 Peachtree Corners East, Suite D	 
	 	 	Norcross, GA 30092	 
	 	 	Phone: 770/242-8723	 
	 	 	FAX: 770/242-8639	 
	 	 	 	 
	 	If to KMTC	Tamaki Nara	 
	 	 	Konica Minolta Technology Center, Inc.	 
	 	 	1 Sakura-machi, Hino-shi	 
	 	 	Tokyo 191-8511, Japan	 

 

	The Parties to this Agreement are and
shall remain independent contractors and nothing herein shall be construed to create a partnership, agency or joint venture between
the parties. Each party shall be responsible for wages, hours and conditions of employment of its personnel during the term of,
and under, this Agreement.
	All questions concerning the validity,
operation, interpretation and construction of this Agreement will be governed by and determined in accordance with the laws of
the State of New York excluding its conflict of laws provisions.
	All disputes which may arise between
the parties hereto, out of or in relation to this Agreement, shall be finally settled by arbitration in Tokyo, Japan pursuant to
the Commercial Arbitration Rules of The Japan Commercial Arbitration Association if GT requests the arbitration or in Atlanta,
Georgia pursuant to the Commercial Arbitration Rules of the American Arbitration Association ifKMTC requests the arbitration.
	Notwithstanding the contrary provisions
of Section 13d, the parties hereto shall have the right to apply for and obtain a temporary restraining order or other temporary,
interim or permanent injunctive or equitable relief from a court of competent jurisdiction in order to enforce the provisions of
this Agreement as may be necessary to obtain specific performance or injunctive relief.
	No waiver by either party of any breach
of any provision hereof shall constitute a waiver of any other breach of that provision or any other provision thereof.
	Each party represents and warrants
that the terms of this Agreement are not inconsistent with any other contractual or legal obligations it may have or with the policies
of any institution or company with which such party is associated.
	The parties have participated jointly
in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of intent or interpretation arises,
this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring
or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.
	This Agreement may be signed by the
parties in counterparts and via facsimile, which signatures, taken as a whole, shall constitute an effective Agreement.
	J. Neither this Agreement nor any rights
hereunder may be transferred or assigned by either party without the prior written consent of the other party except pursuant to
a merger, acquisition or sale of substantially all of such party's business assets to which this Agreement relates.
	This Agreement, sets forth the entire
agreement and understanding between the parties as to the subject matter hereof and merges all prior discussions between them;
and neither party shall be bound by any conditions, definitions, warranties, understandings or representations with respect to
such subject matter other than as expressly provided herein. This Agreement may not be modified or altered except in writing by
an instrument duly executed by authorized officers of both parties.
	Nothing herein expressed or implied
is intended or should be construed to confer upon or give to any person other than the parties hereto and their successors and
permitted assigns any rights or remedies under, or by reason of this Agreement.

 

IN WITNESS WHEREOF, the
parties hereto have caused tills Agreement to be duly executed by their duly authorized officers as of the 19 day
of June 2012.

	
	GT KMTC	 	KMTC
	5835 Peachtree Corners East Suite D	 	1 Sakura-machi, Hino-shi
	Norcross, Georgia 30092	 	Tokyo 191-8511, Japan
	 	 	 
	 	 	 
	By: /s/ Mark Faupel	 	By: /s/ Tamaki Nara
	Mark Faupel, PhD	 	Tamaki Nara
	President and CEO	 	General Manager
	 	 	Business Development Center
	 	 	LC Business Department

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]